DOGWOOD THERAPEUTICS INC (DWTX) Fundamental Analysis & Valuation
NASDAQ:DWTX • US92829J2033
Current stock price
3.06 USD
0 (0%)
At close:
3.01 USD
-0.05 (-1.63%)
After Hours:
This DWTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. DWTX Profitability Analysis
1.1 Basic Checks
- DWTX had negative earnings in the past year.
- In the past year DWTX has reported a negative cash flow from operations.
- In the past 5 years DWTX always reported negative net income.
- In the past 5 years DWTX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -43.46%, DWTX perfoms like the industry average, outperforming 54.83% of the companies in the same industry.
- DWTX has a better Return On Equity (-51.66%) than 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.46% | ||
| ROE | -51.66% | ||
| ROIC | N/A |
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- DWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. DWTX Health Analysis
2.1 Basic Checks
- The number of shares outstanding for DWTX has been increased compared to 1 year ago.
- The number of shares outstanding for DWTX has been reduced compared to 5 years ago.
- There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- DWTX has an Altman-Z score of 1.58. This is a bad value and indicates that DWTX is not financially healthy and even has some risk of bankruptcy.
- DWTX has a Altman-Z score of 1.58. This is in the better half of the industry: DWTX outperforms 64.48% of its industry peers.
- DWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.58 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- DWTX has a Current Ratio of 4.49. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
- DWTX has a Current ratio (4.49) which is in line with its industry peers.
- DWTX has a Quick Ratio of 4.49. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
- DWTX has a Quick ratio (4.49) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.49 | ||
| Quick Ratio | 4.49 |
3. DWTX Growth Analysis
3.1 Past
- DWTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -209.16%.
EPS 1Y (TTM)-209.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 17.79% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-58.18%
EPS Next 2Y26.51%
EPS Next 3Y17.79%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. DWTX Valuation Analysis
4.1 Price/Earnings Ratio
- DWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DWTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as DWTX's earnings are expected to grow with 17.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.51%
EPS Next 3Y17.79%
5. DWTX Dividend Analysis
5.1 Amount
- No dividends for DWTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
DWTX Fundamentals: All Metrics, Ratios and Statistics
3.06
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners11.09%
Inst Owner Change26.32%
Ins Owners0.01%
Ins Owner Change99.03%
Market Cap101.90M
Revenue(TTM)N/A
Net Income(TTM)-39.98M
Analysts82.5
Price Target19.38 (533.33%)
Short Float %0.68%
Short Ratio1.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-279.47%
Min EPS beat(2)-556.26%
Max EPS beat(2)-2.68%
EPS beat(4)0
Avg EPS beat(4)-234.65%
Min EPS beat(4)-556.26%
Max EPS beat(4)-2.68%
EPS beat(8)2
Avg EPS beat(8)-127.97%
EPS beat(12)5
Avg EPS beat(12)-75.54%
EPS beat(16)9
Avg EPS beat(16)-50.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-20.25
EYN/A
EPS(NY)-4.36
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS2.32
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.46% | ||
| ROE | -51.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.49 | ||
| Quick Ratio | 4.49 | ||
| Altman-Z | 1.58 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-209.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-58.18%
EPS Next 2Y26.51%
EPS Next 3Y17.79%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-390.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-198.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.34%
OCF growth 3YN/A
OCF growth 5YN/A
DOGWOOD THERAPEUTICS INC / DWTX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of DOGWOOD THERAPEUTICS INC (DWTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to DWTX.
What is the valuation status of DOGWOOD THERAPEUTICS INC (DWTX) stock?
ChartMill assigns a valuation rating of 0 / 10 to DOGWOOD THERAPEUTICS INC (DWTX). This can be considered as Overvalued.
Can you provide the profitability details for DOGWOOD THERAPEUTICS INC?
DOGWOOD THERAPEUTICS INC (DWTX) has a profitability rating of 1 / 10.
What is the financial health of DOGWOOD THERAPEUTICS INC (DWTX) stock?
The financial health rating of DOGWOOD THERAPEUTICS INC (DWTX) is 7 / 10.